SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Support for Patients 
and Communities Reauthorization Act’’. 
SEC. 2. TABLE OF CONTENTS. 
The table of contents for this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—PUBLIC HEALTH 
Sec. 101. Prenatal and postnatal health. 
Sec. 102. Monitoring and education regarding infections associated with illicit 
drug use and other risk factors. 
Sec. 103. Preventing overdoses of controlled substances. 
Sec. 104. Residential treatment programs for pregnant and postpartum women. 
Sec. 105. Youth prevention and recovery. 
Sec. 106. First responder training. 
Sec. 107. Building communities of recovery. 
Sec. 108. National Peer-Run Training and Technical Assistance Center for Ad-
diction Recovery Support. 
Sec. 109. Comprehensive opioid recovery centers. 
Sec. 110. Grants to address the problems of persons who experience violence re-
lated stress. 
Sec. 111. Mental and behavioral health education and training grants. 
Sec. 112. Loan repayment program for the substance use disorder treatment 
workforce. 
Sec. 113. Pilot program for public health laboratories to detect fentanyl and 
other synthetic opioids. 
Sec. 114. Monitoring and reporting of child, youth, and adult trauma. 
Sec. 115. Task force to develop best practices for trauma-informed identifica-
tion, referral, and support. 
Sec. 116. Treatment, recovery, and workforce support grants. 
Sec. 117. Grant program for State and Tribal response to opioid use disorders. 
Sec. 118. References to opioid overdose reversal agents in HHS grant pro-
grams. 
Sec. 119. Addressing other concurrent substance use disorders through grant 
program for State and Tribal response to opioid use disorders. 
Sec. 120. Providing for a study on the effects of remote monitoring on individ-
uals who are prescribed opioids. 
TITLE II—CONTROLLED SUBSTANCES 
Sec. 201. Delivery of certain substances by a pharmacy to an administering 
practitioner. 
Sec. 202. Reviewing the scheduling of approved products containing a combina-
tion of buprenorphine and naloxone. 
Sec. 203. Combating illicit xylazine. 
Sec. 204. Technical corrections. 
Sec. 205. Required training for prescribers of controlled substances. 
TITLE III—MEDICAID
Sec. 301. Extending requirement for State Medicaid plans to provide coverage 
for medication-assisted treatment. 
Sec. 302. Expanding required reports on T-MSIS substance use disorder data 
to include mental health condition data. 
Sec. 303. Monitoring prescribing of antipsychotic medications. 
Sec. 304. Lifting the IMD exclusion for substance use disorder. 
Sec. 305. Prohibition on termination of enrollment due to incarceration. 
Sec. 306. State option relating to inmates who are pregnant women pending 
disposition of charges. 
Sec. 307. Permitting access to medical assistance under the Medicaid program 
for foster youth. 
TITLE IV—OFFSETS 
Sec. 401. Promoting value in Medicaid managed care. 
TITLE I—PUBLIC HEALTH 
SEC. 101. PRENATAL AND POSTNATAL HEALTH. 
Section 317L(d) of the Public Health Service Act (42 
U.S.C. 247b–13(d)) is amended by striking ‘‘such sums 
as may be necessary for each of the fiscal years 2019 
through 2023’’ and inserting ‘‘$4,250,000 for each of fis-
cal years 2024 through 2028’’. 
SEC. 102. MONITORING AND EDUCATION REGARDING IN-
FECTIONS ASSOCIATED WITH ILLICIT DRUG 
USE AND OTHER RISK FACTORS. 
Section 317N of the Public Health Service Act (42 
U.S.C. 247b–15) is amended— 
(1) in the section heading, by striking ‘‘SUR-
VEILLANCE
AND’’ and inserting ‘‘MONITORING 
AND’’ ; and 
(2) in subsection (d), by striking ‘‘fiscal years 
2019 through 2023’’ and inserting ‘‘fiscal years 
2024 through 2028’’.
SEC. 103. PREVENTING OVERDOSES OF CONTROLLED SUB-
STANCES. 
(a) EVIDENCE-BASED PREVENTION GRANTS.—Sec-
tion 392A(a)(2)(D) of the Public Health Service Act (42 
U.S.C. 280b–1(a)(2)(D)) is amended by inserting after 
‘‘new and emerging public health crises’’ the following: ‘‘, 
such as the fentanyl crisis,’’. 
(b) USE OF GRANTS BY STATES, LOCALITIES, AND 
INDIAN TRIBES TO CONDUCT WASTEWATER SURVEIL-
LANCE.—Section 392A(a)(3)(A) of the Public Health 
Service Act (42 U.S.C. 280b–1(a)(3)(A)) is amended by 
inserting ‘‘, including through the use of wastewater sur-
veillance to identify trends associated with controlled sub-
stance use if it is determined by appropriate evidence that 
wastewater surveillance is an effective way to survey con-
trolled substance use within a community’’ before the 
semicolon. 
(c) AUTHORIZATION OF APPROPRIATIONS.—Section 
392A(e) of the Public Health Service Act (42 U.S.C. 
280b–1(e)) is amended by striking ‘‘$496,000,000 for 
each of fiscal years 2019 through 2023’’ and inserting 
‘‘$505,579,000 for each of fiscal years 2024 through 
2028’’.
SEC. 
104. 
RESIDENTIAL 
TREATMENT 
PROGRAMS 
FOR 
PREGNANT AND POSTPARTUM WOMEN. 
Section 508(s) of the Public Health Service Act (42 
U.S.C. 290bb–1(s)) is amended by striking ‘‘$29,931,000 
for each of fiscal years 2019 through 2023’’ and inserting 
‘‘$38,931,000 for each of fiscal years 2024 through 
2028’’. 
SEC. 105. YOUTH PREVENTION AND RECOVERY. 
Section 7102(c)(9) of the SUPPORT for Patients 
and Communities Act (42 U.S.C. 290bb–7a(c)(9)) is 
amended by striking ‘‘fiscal years 2019 through 2023’’ 
and inserting ‘‘fiscal years 2024 through 2028’’. 
SEC. 106. FIRST RESPONDER TRAINING. 
Section 546(h) of the Public Health Service Act (42 
U.S.C. 290ee–1(h)) is amending by striking ‘‘$36,000,000 
for each of fiscal years 2019 through 2023’’ and inserting 
‘‘$56,000,000 for each of fiscal years 2024 through 
2028’’. 
SEC. 107. BUILDING COMMUNITIES OF RECOVERY. 
Section 547(f) of the Public Health Service Act (42 
U.S.C. 290ee–2(f)) is amended by striking ‘‘$5,000,000 
for each of fiscal years 2019 through 2023’’ and inserting 
‘‘$16,000,000 for each of fiscal years 2024 through 
2028’’.
SEC. 108. NATIONAL PEER-RUN TRAINING AND TECHNICAL 
ASSISTANCE CENTER FOR ADDICTION RE-
COVERY SUPPORT. 
Section 547A(e) of the Public Health Service Act (42 
U.S.C. 290ee–2a(e)) is amended by striking ‘‘$1,000,000 
for each of fiscal years 2019 through 2023’’ and inserting 
‘‘$2,000,000 for each of fiscal years 2024 through 2028’’. 
SEC. 109. COMPREHENSIVE OPIOID RECOVERY CENTERS. 
(a) REAUTHORIZATION.—Section 552(j) of the Public 
Health Service Act (42 U.S.C. 290ee–7(j)) is amended by 
striking ‘‘2019 through 2023’’ and inserting ‘‘2024 
through 2028’’. 
(b) DOCUMENTATION FOR EVIDENCE OF CAPACITY 
TO CARRY OUT REQUIRED ACTIVITIES.—Section 552(d) 
of the Public Health Service Act (42 U.S.C. 290ee–7(d)) 
is amended by adding at the end the following: 
‘‘(3) DOCUMENTATION.— 
‘‘(A) IN GENERAL.—Evidence required to 
be provided under paragraph (1) may be pro-
vided through a letter of intent from partner 
agencies or other relevant documentation (as 
defined by the Secretary). 
‘‘(B) PARTNER AGENCY DEFINED.—In this 
paragraph, the term ‘partner agency’ means a 
non-governmental organization or other public 
or private entity—
‘‘(i) the primary purpose of which is 
the delivery of mental health or substance 
use disorder treatment services; and 
‘‘(ii) with which the applicant coordi-
nates to provide the full continuum of 
treatment services (as specified in sub-
section (g)(1)(B)) that the applicant is un-
able to offer on site.’’. 
(c) CENTER ACTIVITIES CARRIED OUT THROUGH 
THIRD PARTIES.—Section 552(g) of the Public Health 
Service Act (42 U.S.C. 290ee–7(g)) is amended in the 
matter preceding paragraph (1) by striking ‘‘Each Center 
shall’’ and all that follows through ‘‘subsection (f):’’ and 
inserting the following: ‘‘Each Center shall, at a minimum, 
carry out the activities specified in this subsection directly, 
through referral, or through contractual arrangements. If 
a Center elects to carry out such activities through con-
tractual arrangements, the Secretary may issue guidance 
on best practices to ensure that the Center is capable of 
carrying out such activities, including carrying out such 
activities through technology-enabled collaborative learn-
ing and capacity building models described in subsection 
(f) and coordinating the full continuum of treatment serv-
ices specified in subparagraph (B). Such activities include 
the following:’’.
SEC. 110. GRANTS TO ADDRESS THE PROBLEMS OF PER-
SONS WHO EXPERIENCE VIOLENCE RELATED 
STRESS. 
Section 582(j) of the Public Health Service Act (42 
U.S.C. 290hh–1(j)) is amended by striking ‘‘$63,887,000 
for each of fiscal years 2019 through 2023’’ and inserting 
‘‘$93,887,000 for each of fiscal years 2024 through 
2028’’. 
SEC. 111. MENTAL AND BEHAVIORAL HEALTH EDUCATION 
AND TRAINING GRANTS. 
Section 756(f) of the Public Health Service Act (42 
U.S.C. 294e–1(f)) is amended by striking ‘‘fiscal years 
2023 through 2027’’ and inserting ‘‘fiscal years 2024 
through 2028’’. 
SEC. 112. LOAN REPAYMENT PROGRAM FOR THE SUB-
STANCE USE DISORDER TREATMENT WORK-
FORCE. 
Section 781(j) of the Public Health Service Act (42 
U.S.C. 295h(j)) is amended by striking ‘‘$25,000,000 for 
each of fiscal years 2019 through 2023’’ and inserting 
‘‘$40,000,000 for each of fiscal years 2024 through 
2028’’.
SEC. 113. PILOT PROGRAM FOR PUBLIC HEALTH LABORA-
TORIES TO DETECT FENTANYL AND OTHER 
SYNTHETIC OPIOIDS. 
(a) DETECTION ACTIVITIES.—Section 7011(b) of the 
SUPPORT for Patients and Communities Act (42 U.S.C. 
247d–10 note) is amended— 
(1) in paragraph (2), by striking ‘‘and’’ at the 
end; 
(2) in paragraph (3), by striking the period at 
the end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(4) public, private, and academic entities with 
expertise in detection and testing activities, such as 
wastewater surveillance, with respect to synthetic 
opioids, including fentanyl and its analogues.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—Section 
7011(d) of the SUPPORT for Patients and Communities 
Act (42 U.S.C. 247d–10(d)) is amended by striking ‘‘fiscal 
years 2019 through 2023’’ and inserting ‘‘fiscal years 
2024 through 2028’’. 
SEC. 114. MONITORING AND REPORTING OF CHILD, YOUTH, 
AND ADULT TRAUMA. 
Section 7131(e) of the SUPPORT for Patients and 
Communities Act (42 U.S.C. 242t(e)) is amended by strik-
ing ‘‘$2,000,000 for each of fiscal years 2019 through
2023’’ and inserting ‘‘$9,000,000 for each of fiscal years 
2024 through 2028’’. 
SEC. 115. TASK FORCE TO DEVELOP BEST PRACTICES FOR 
TRAUMA-INFORMED 
IDENTIFICATION, 
RE-
FERRAL, AND SUPPORT. 
Section 7132 of the SUPPORT for Patients and 
Communities Act (Public Law 115–271) is amended— 
(1) in subsection (g)— 
(A) in paragraph (1), by striking ‘‘and’’ at 
the end; 
(B) in paragraph (2), by striking the pe-
riod at the end and inserting ‘‘; and’’; and 
(C) by adding at the end the following: 
‘‘(3) additional reports and updates to existing 
reports, as necessary.’’; and 
(2) by amending subsection (i) to read as fol-
lows: 
‘‘(i) SUNSET.—The task force shall sunset on Sep-
tember 30, 2026.’’. 
SEC. 116. TREATMENT, RECOVERY, AND WORKFORCE SUP-
PORT GRANTS. 
Section 7183 of the SUPPORT for Patients and 
Communities Act (42 U.S.C. 290ee–8) is amended— 
(1) in subsection (b), by inserting ‘‘each’’ before 
‘‘for a period’’;
(2) by amending subsection (c)(2) to read as 
follows: 
‘‘(2) RATES.—The rates described in this para-
graph are the following: 
‘‘(A) The amount by which the average 
rate of drug overdose deaths in the State, ad-
justed for age, for the period of 5 calendar 
years for which there is available data, includ-
ing if necessary provisional data, immediately 
preceding the grant cycle (which shall be the 
period of calendar years 2018 through 2022 for 
the first grant cycle following the enactment of 
the Support for Patients and Communities Re-
authorization Act) is above the average national 
overdose mortality rate, as determined by the 
Director of the Centers for Disease Control and 
Prevention, for the same period. 
‘‘(B) The amount by which the average 
rate of unemployment for the State, based on 
data provided by the Bureau of Labor Statis-
tics, for the period of 5 calendar years for 
which there is available data, including if nec-
essary provisional data, immediately preceding 
the grant cycle (which shall be the period of cal-
endar years 2018 through 2022 for the first
grant cycle following the enactment of the Sup-
port for Patients and Communities Reauthor-
ization Act) is above the national average for 
the same period. 
‘‘(C) The amount by which the average 
rate of labor force participation in the State, 
based on data provided by the Bureau of Labor 
Statistics, for the period of 5 calendar years for 
which there is available data, including if nec-
essary provisional data, immediately preceding 
the grant cycle (which shall be the period of cal-
endar years 2018 through 2022 for the first 
grant cycle following the enactment of the Sup-
port for Patients and Communities Reauthor-
ization Act) is below the national average for 
the same period.’’; 
(3) in subsection (g)— 
(A) in paragraphs (1) and (3), by redesig-
nating subparagraphs (A) and (B) as clauses 
(i) and (ii), respectively, and adjusting the mar-
gins accordingly; 
(B) 
by 
redesignating 
paragraphs 
(1) 
through (3) as subparagraphs (A) through (C), 
respectively, and adjusting the margins accord-
ingly;
(C) by striking ‘‘An entity’’ and inserting 
the following: 
‘‘(1) IN GENERAL.—An entity’’; and 
(D) by adding at the end the following: 
‘‘(2) TRANSPORTATION
SERVICES.—An entity 
receiving a grant under this section may use not 
more than 5 percent of the funds for providing 
transportation for individuals to participate in an ac-
tivity supported by a grant under this section, which 
transportation shall be to or from a place of work 
or a place where the individual is receiving voca-
tional education or job training services or receiving 
services directly linked to treatment of or recovery 
from a substance use disorder. 
‘‘(3) NO OTHER AUTHORIZED USES.—An entity 
receiving a grant under this section may not use the 
funds for any activity other than the activities listed 
in paragraphs (1) and (2).’’; 
(4) in subsection (i)(2), by inserting ‘‘, which 
shall include the employment and earnings outcomes 
as described in subclauses (I) and (III) of section 
116(b)(2)(A)(i) of the Workforce Innovation and 
Opportunity Act (29 U.S.C. 3141(b)(2)(A)(i))’’ after 
‘‘subsection (g)’’; 
(5) in subsection (j)—
SEC. 118. REFERENCES TO OPIOID OVERDOSE REVERSAL 
AGENTS IN HHS GRANT PROGRAMS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall ensure that, as appropriate, when-
ever the Department of Health and Human Services 
issues a regulation or guidance for any grant program ad-
dressing opioid misuse and use disorders, any reference 
to an opioid overdose reversal drug (such as a reference 
to naloxone) is inclusive of any opioid overdose reversal 
drug that has been approved under section 505 of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 355) for 
emergency treatment of a known or suspected opioid over-
dose. 
(b) EXISTING REFERENCES.— 
(1) UPDATE.—Not later than one year after the 
date of enactment of this Act, the Secretary of 
Health and Human Services shall update all ref-
erences described in paragraph (2) to be inclusive of 
any opioid overdose reversal drug that has been ap-
proved or otherwise authorized for use by the Food 
and Drug Administration. 
(2) REFERENCES.—A reference described in 
this paragraph is any reference to an opioid overdose 
reversal drug (such as naloxone) in any regulation or 
guidance of the Department of Health and Human 
Services that—
(A) was issued before the date of enact-
ment of this Act; and 
(B) is included in— 
(i) the grant program for State and 
Tribal response to opioid use disorders 
under section 1003 of the 21st Century 
Cures Act (42 U.S.C. 290ee–3 note) (com-
monly referred to as ‘‘State Opioid Re-
sponse Grants’’ and ‘‘Tribal Opioid Re-
sponse Grants’’); or 
(ii) the grant program for priority 
substance use disorder prevention needs of 
regional and national significance under 
section 516 of the Public Health Service 
Act (42 U.S.C. 290bb–22). 
SEC. 119. ADDRESSING OTHER CONCURRENT SUBSTANCE 
USE DISORDERS THROUGH GRANT PROGRAM 
FOR 
STATE 
AND 
TRIBAL 
RESPONSE 
TO 
OPIOID USE DISORDERS. 
(a) ADDITIONAL USE OF FUNDS.—Section 1003(b) 
of the 21st Century Cures Act (42 U.S.C. 290ee–3 note) 
is amended by adding at the end the following: 
‘‘(5) OTHER
CONCURRENT
SUBSTANCE
USE 
DISORDERS.—The Secretary may authorize the re-
cipient of a grant under this subsection, in addition
to using the grant for activities described in para-
graph (4) with respect to opioid misuse and use dis-
orders and stimulant misuse and use disorders, to 
use the grant for similar activities with respect to 
other concurrent substance use disorders.’’. 
(b) ANNUAL
REPORT
TO
CONGRESS.—Section 
1003(f) of the 21st Century Cures Act (42 U.S.C. 290ee– 
3 note) is amended— 
(1) in paragraph (2), strike ‘‘and’’ at the end; 
(2) in paragraph (3), strike the period at the 
end and insert a semicolon; and 
(3) by adding at the end the following: 
‘‘(4) the amount of funds each State that re-
ceived a grant under subsection (b) received for the 
12-month grant cycle covered by the report; 
‘‘(5) the amount of grant funds each such State 
spent for such grant cycle, disaggregated by the uses 
for which such funds were spent, including each al-
lowable use under paragraphs (4) and (5) of sub-
section (b); 
‘‘(6) how many such States for such grant cycle 
did not spend all of the grant funds before such 
grant cycle expired;
‘‘(7) how many such States for such grant cycle 
requested no-cost extensions to extend the grant 
cycle; and 
‘‘(8) challenges for such States to spend all of 
the funds allocated and the reason for such chal-
lenges, including to what extent reporting require-
ments or other requirements placed an increased 
burden on the ability of such States to spend all of 
the funds.’’. 
(c) OTHER CONCURRENT SUBSTANCE USE DIS-
ORDERS DEFINED.—Section 1003(h) of the 21st Century 
Cures Act (42 U.S.C. 290ee–3 note) is amended— 
(1) by redesignating paragraphs (2) through 
(4) as paragraphs (3) through (5); and 
(2) by inserting before paragraph (3), as redes-
ignated, the following: 
‘‘(2) OTHER
CONCURRENT
SUBSTANCE
USE 
DISORDERS.—The term ‘other concurrent substance 
use disorders’ means— 
‘‘(A) alcohol use disorders co-occurring 
with opioid misuse and use disorders as a pri-
mary disorder; or 
‘‘(B) alcohol use disorders co-occurring 
with stimulant misuse and use disorders as a 
primary disorder.’’.
(d) RULE OF CONSTRUCTION.—Nothing in this Act 
or the amendments made by this Act shall be construed 
to change the allocation of funds among grantees pursuant 
to the minimum allocations and formula methodology 
under section 1003 of the 21st Century Cures Act (42 
U.S.C. 290ee–3 note). 
SEC. 120. PROVIDING FOR A STUDY ON THE EFFECTS OF 
REMOTE MONITORING ON INDIVIDUALS WHO 
ARE PRESCRIBED OPIOIDS. 
(a) IN GENERAL.—Not later than 18 months after 
the date of enactment of this Act, the Comptroller General 
of the United States shall conduct a study and submit to 
the Committee on Energy and Commerce of the House 
of Representatives and the Committee on Health, Edu-
cation, Labor, and Pensions and the Committee on Fi-
nance of the Senate a report on the use of remote moni-
toring with respect to individuals who are prescribed 
opioids. 
(b) REPORT.—The report described in subsection (a) 
shall include to the extent information is available and re-
liable— 
(1) an assessment of scientific evidence related 
to the efficacy, individual outcomes, and potential 
cost savings associated with remote monitoring for
individuals who are prescribed opioids compared to 
such individuals who are not so monitored; 
(2) an assessment of the current prevalence of 
remote monitoring for individuals who are prescribed 
opioids, including the use of such monitoring for 
such individuals in other countries; and 
(3) information, including recommendations as 
appropriate, to improve availability, access, and cov-
erage for remote monitoring for individuals who are 
prescribed opioids, including through changes to 
Federal health care programs (as defined in section 
1128B of the Social Security Act (42 U.S.C. 1320a– 
7b)). 
TITLE II—CONTROLLED 
SUBSTANCES 
SEC. 201. DELIVERY OF CERTAIN SUBSTANCES BY A PHAR-
MACY 
TO 
AN 
ADMINISTERING 
PRACTI-
TIONER. 
Paragraph (2) of section 309A(a) of the Controlled 
Substances Act (21 U.S.C. 829a(a)) is amended to read 
as follows: 
‘‘(2) the controlled substance is a drug in 
schedule III, IV, or V that is, pursuant to the ap-
proval or licensure of such drug under the Federal 
Food, Drug, and Cosmetic Act or section 351 of the
Public Health Service Act, to be administered by, or 
under the supervision of, the prescribing practi-
tioner;’’. 
SEC. 202. REVIEWING THE SCHEDULING OF APPROVED 
PRODUCTS CONTAINING A COMBINATION OF 
BUPRENORPHINE AND NALOXONE. 
(a) SECRETARY OF HHS.—The Secretary of Health 
and Human Services shall, consistent with the require-
ments and procedures set forth in sections 201 and 202 
of the Controlled Substances Act (21 U.S.C. 811; 812)— 
(1) review the relevant data pertaining to the 
scheduling of products containing a combination of 
buprenorphine and naloxone that have been ap-
proved under section 505 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355); and 
(2) if appropriate, request that the Attorney 
General initiate rulemaking proceedings to revise the 
schedules accordingly with respect to such products. 
(b) ATTORNEY GENERAL.—The Attorney General 
shall review any request made by the Secretary of Health 
and Human Services under subsection (a)(2) and deter-
mine whether to initiate proceedings to revise the sched-
ules in accordance with the criteria set forth in sections 
201 and 202 of the Controlled Substances Act (21 U.S.C. 
811; 812).
‘‘(i) such substance is an animal drug that has 
been approved by the Secretary of Health and 
Human Services under section 512 of the Federal 
Food, Drug, and Cosmetic Act and such substance’s 
use or intended use conforms to the approved appli-
cation, including the manufacturing, importation, 
holding, or distribution for such use; or 
‘‘(ii) such substance is used or intended for use 
in animals other than humans as permitted under 
section 512(a)(4) of the Federal Food, Drug, and 
Cosmetic Act. 
‘‘(C) If any person prescribes, dispenses, distributes, 
manufactures, or imports xylazine for human use, such 
person shall be considered to have prescribed, dispensed, 
distributed, manufactured, or imported xylazine not sub-
ject to an exclusion under subparagraph (B).’’. 
(b) PLACEMENT OF XYLAZINE ON SCHEDULE III.— 
Schedule III in section 202(c) of the Controlled Sub-
stances Act (21 U.S.C. 812(c)) is amended by adding at 
the end the following: 
‘‘(f) Xylazine.’’. 
(c) ARCOS TRACKING.—Section 307(i) of the Con-
trolled Substances Act (21 U.S.C. 827(i)) is amended— 
(1) in the matter preceding paragraph (1)—
(A) by inserting ‘‘or xylazine’’ after 
‘‘gamma hydroxybutyric acid’’; 
(B) by inserting ‘‘or 512’’ after ‘‘section 
505’’; and 
(C) by inserting ‘‘respectively,’’ after ‘‘the 
Federal Food, Drug, and Cosmetic Act,’’; and 
(2) in paragraph (6), by inserting ‘‘or xylazine’’ 
after ‘‘gamma hydroxybutyric acid’’. 
(d) REPORT TO CONGRESS ON XYLAZINE.— 
(1) INITIAL REPORT.—Not later than 1 year 
after the date of enactment of this Act, the Attorney 
General, acting through the Administrator of the 
Drug Enforcement Administration and in coordina-
tion with the Commissioner of Food and Drugs, 
shall submit to Congress a report on the prevalence 
of illicit use of xylazine in the United States and the 
impacts of such use, including— 
(A) where the drug is being diverted; 
(B) where the drug is originating; 
(C) whether any analogues to such drug 
present a substantial risk of abuse; 
(D) whether and to what extent the illicit 
supply of xylazine derives from the licit supply 
chain; and
(E) recommendations for Congress with re-
spect to whether xylazine should be transferred 
to another schedule under section 202 of the 
Controlled Substances Act (21 U.S.C. 812). 
(2) ADDITIONAL
REPORT.—Not later than 3 
years after the date of enactment of this Act, the 
Attorney General, acting through the Administrator 
of the Drug Enforcement Administration and in co-
ordination with the Commissioner of Food and 
Drugs, shall submit to Congress a report updating 
Congress on the prevalence of xylazine trafficking, 
misuse, and proliferation in the United States, in-
cluding— 
(A) the status and results of research on 
the impact xylazine has on human health; and 
(B) the effects of the classification of 
xylazine under the Controlled Substances Act 
(21 U.S.C. 801 et seq.) on the prevalence of 
xylazine trafficking, misuse, and proliferation in 
the United States. 
(3) OBTAINING OFFICIAL DATA.—The Attorney 
General, acting through the Administrator of the 
Drug Enforcement Administration and in coordina-
tion with the Commissioner of Food and Drugs, may 
secure directly from any department or agency of
the United States documents, statistical data, and 
other information necessary to carry out paragraphs 
(1) and (2). Upon receipt of a request from the At-
torney General for such documents, data, and infor-
mation, the head of the department or agency shall, 
in accordance with applicable procedures for the ap-
propriate handling of classified information, prompt-
ly provide reasonable access to such documents, 
data, and information. 
(4) VIEWS OF EXPERTS FROM NON-FEDERAL 
ENTITIES.—In developing the reports under para-
graphs (1) and (2), the Attorney General, acting 
through the Administrator of the Drug Enforcement 
Administration and in coordination with the Com-
missioner of Food and Drugs, shall consult with, 
and take into consideration the views of, experts 
from appropriate non-Federal entities, including 
such experts from— 
(A) the scientific and medical research 
community; 
(B) the State and local law enforcement 
community; and 
(C) community-based organizations.
SEC. 204. TECHNICAL CORRECTIONS. 
Effective as if included in the enactment of Public 
Law 117–328— 
(1) section 1252(a) of division FF of Public 
Law 117–328 is amended, in the matter being in-
serted into section 302(e) of the Controlled Sub-
stances Act, by striking ‘‘303(g)’’ and inserting 
‘‘303(h)’’; 
(2) section 1262 of division FF of Public Law 
117–328 is amended— 
(A) in subsection (a)— 
(i) in the matter preceding paragraph 
(1), by striking ‘‘303(g)’’ and inserting 
‘‘303(h)’’; 
(ii) in the matter being stricken by 
subsection (a)(2), by striking ‘‘(g)(1)’’ and 
inserting ‘‘(h)(1)’’; and 
(iii) in the matter being inserted by 
subsection (a)(2), by striking ‘‘(g) Practi-
tioners’’ and inserting ‘‘(h) Practitioners’’; 
and 
(B) in subsection (b)— 
(i) in the matter being stricken by 
paragraph (1), by striking ‘‘303(g)(1)’’ 
and inserting ‘‘303(h)(1)’’;
(ii) in the matter being inserted by 
paragraph (1), by striking ‘‘303(g)’’ and 
inserting ‘‘303(h)’’; 
(iii) in the matter being stricken by 
paragraph (2)(A), by striking ‘‘303(g)(2)’’ 
and inserting ‘‘303(h)(2)’’; 
(iv) in the matter being stricken by 
paragraph (3), by striking ‘‘303(g)(2)(B)’’ 
and inserting ‘‘303(h)(2)(B)’’; 
(v) in the matter being stricken by 
paragraph (5), by striking ‘‘303(g)’’ and 
inserting ‘‘303(h)’’; and 
(vi) in the matter being stricken by 
paragraph (6), by striking ‘‘303(g)’’ and 
inserting ‘‘303(h)’’; and 
(3) section 1263(b) of division FF of Public 
Law 117–328 is amended— 
(A) by striking ‘‘303(g)(2)’’ and inserting 
‘‘303(h)(2)’’; and 
(B) by striking ‘‘(21 U.S.C. 823(g)(2))’’ 
and inserting ‘‘(21 U.S.C. 823(h)(2))’’. 
SEC. 205. REQUIRED TRAINING FOR PRESCRIBERS OF CON-
TROLLED SUBSTANCES. 
Section 303 of the Controlled Substances Act (21 
U.S.C. 823) is amended—